LAPTM 4 B Polymorphisms is Associated with Ovarian Cancer Susceptibility and Its Prognosis

Objective: Lysosome-associated protein transmembrane 4 beta (LAPTM4B) is an important novel gene associated with the proliferation and differentiation of cells. Recent studies have shown that it was overexpressed in many cancer tissues. This study investigated the association between different LAPTM4B polymorphisms and the susceptibility and prognosis of ovarian cancer. Methods: A case–control study was performed in 282 patients with ovarian cancer and 365 control subjects. Genomic DNA was extracted from peripheral blood lymphocytes in all participants. LAPTM4B genotypes were determined using polymerase chain reaction. Results: There was a significantly higher LAPTM4B*2 allele frequency in ovarian cancer cases than controls (P , 0.05). Using the LAPTM4B*1/1 genotype as the reference, we found that the LAPTM4B*1/2 and LAPTM4B*2/2 genotypes were positively associated with ovarian cancer. Additionally, we found a negative correlation between the tumor grade and LAPTM4B allele genotype, which indicates strongly that LAPTM4B*2 could affect the survival of patients. Conclusions: These findings indicate that the LAPTM4B*2 allele may be a risk factor for ovarian cancer and may play an important role in genetic susceptibility to ovarian cancer.

[1]  Ming-zhu Yin,et al.  LAPTM4B overexpression is a novel predictor of epithelial ovarian carcinoma metastasis , 2011, International journal of cancer.

[2]  Ming-zhu Yin,et al.  Correlation of LAPTM4B polymorphisms with cervical carcinoma , 2011, Cancer.

[3]  Ming-zhu Yin,et al.  Overexpression of LAPTM4B-35 in Cervical Carcinoma: A Clinicopathologic Study , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[4]  Ming-zhu Yin,et al.  LAPTM4B-35 Overexpression Is an Independent Prognostic Marker in Endometrial Carcinoma , 2010, International Journal of Gynecologic Cancer.

[5]  R. Zhou,et al.  LAPTM4B‐35, a novel tetratransmembrane protein and its PPRP motif play critical roles in proliferation and metastatic potential of hepatocellular carcinoma cells , 2009, Cancer science.

[6]  J. Rui,et al.  Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. , 2007, European journal of cancer.

[7]  Y. Liu,et al.  Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Qinghua Zhou,et al.  [Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer]. , 2006, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[9]  J. Rui,et al.  Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[10]  J. Rui,et al.  Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. , 2004, World journal of gastroenterology.

[11]  Jun Liu,et al.  Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma , 2003, Oncogene.

[12]  J. Rui,et al.  [Identification and characterization of LAPTM4B encoded by a human hepatocellular carcinoma-associated novel gene]. , 2003, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[13]  V. Ling,et al.  Lysosome-associated protein transmembrane 4 alpha (LAPTM4 alpha) requires two tandemly arranged tyrosine-based signals for sorting to lysosomes. , 2002, The Biochemical journal.

[14]  C. Jin,et al.  Biological function of a novel gene overexpressed in human hepatocellular carcinoma. , 2000, Chinese Medical Journal.

[15]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  C. Cass,et al.  Mouse transporter protein, a membrane protein that regulates cellular multidrug resistance, is localized to lysosomes. , 1999, Cancer research.

[17]  A. Izzotti,et al.  Drug metabolism polymorphisms as modulators of cancer susceptibility. , 1999, Mutation research.

[18]  V. Ling,et al.  A Mammalian Lysosomal Membrane Protein Confers Multidrug Resistance upon Expression in Saccharomyces cerevisiae * , 1999, The Journal of Biological Chemistry.

[19]  R. Scully.  Histological Typing of Ovarian Tumours , 1999, World Health Organization. International Histological Classification of Tumours.

[20]  I. M. Jones,et al.  Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? , 1998, Mutation research.

[21]  H. Geuze,et al.  Intracellular trafficking of lysosomal membrane proteins , 1996, BioEssays : news and reviews in molecular, cellular and developmental biology.

[22]  C. Cass,et al.  Identification of a Novel Membrane Transporter Associated with Intracellular Membranes by Phenotypic Complementation in the Yeast Saccharomyces cerevisiae(*) , 1996, The Journal of Biological Chemistry.

[23]  C Stern,et al.  THE HARDY-WEINBERG LAW. , 1943, Science.